

Original Research Article

Method Development and Validation of UV-Spectrophotometric Estimation of Hydroxychloroquine Sulphate in Bulk and Pharmaceutical Dosage Form

ABSTRACT

Aims: The devised method for estimating hydroxychloroquine sulphate in bulk and pharmaceutical dose forms (tablets) is the subject of this work. The method can therefore be applied to regular quantitative analysis and stability. The following describes the planned work's goal and scope:

- To create an appropriate spectrophotometric method for tablet-based hydroxychloroquine sulphate estimation.
- Carry out the method's validation.

Methodology: These techniques include the area under curve (AUC) method-I and the A1% solution method based on absorbance measurement, or method-II, both of which are chosen at wavelengths of 329.4 nm using a UV-visible spectrophotometer with a 1 cm matched quartz cell and 0.01N acetic acid with water as a solvent.

Results: Plots of the hydroxychloroquine sulphate absorption spectra in 0.01N acetic acid were made. 329.4 nm was found to be the average maximum. With correlation coefficients of 0.9992 and 0.999 ($r^2 > 0.999$) for AUC and 1%, respectively, and a linear connection between the absorbance and drug concentration in concentration ranges of 5-35 g/mL, it is clear that the method is linear. The percentage of medication calculated by various methods was close to 100.12, and 99.41% of the results were consistent with the label claim of the commercially available tablet formulation. As per ICH requirements, the validation parameter research was completed.

Conclusion: The described UV methods offer good accuracy and precision with reduced limits of detection and quantification. They are straightforward, trustworthy, and highly selective. These disclosed methods are ideal for routine quantitative analysis in pharmaceutical dosage forms due to the decreased time required for analysis of hydroxychloroquine sulphate. The time-saving, low-cost alternative to the expensive high-performance liquid chromatographic technology is the applied spectrophotometric approaches.

Keywords: *Hydroxychloroquine Sulphate, UV-Visible spectroscopy, Validation, Calibration curve, Absorbance, ICH, etc.*

1. INTRODUCTION

The compound hydroxychloroquine sulphate (HCQS), with the chemical formula $C_{18}H_{26}ClN_3O.H_2SO_4$ (Fig. 1), is crystalline in nature, solid, and has the CAS number 747-36-4¹⁻². In order to lessen the toxicity of the parent drug, chloroquine, the hydroxy group was added in 1946, leading to the creation of the first molecule of this substance. According to laboratory research on animals, chloroquine is more hazardous than hydroxychloroquine sulphate. HCQS is a member of the extensive class of 4-amino quinolones with antimalarial action. HCQS was primarily developed as an antimalarial medication, but it also possesses a number of other pharmacological properties. Due to its well-known anti-inflammatory properties, it has been successful in treating lupus erythematosus and rheumatoid arthritis³⁻⁴. Additionally, its efficacy in treating photoallergic reactions has been demonstrated. One of the N-ethyl substituents of CQ that has been hydroxylated is present in an analogue of the compound termed HCQ. It is preferred over CQ when high dosages of drug are required to treat malaria because HCQ has less ocular effects. For Cutaneous Lupus Erythematosus (CLE), hydroxychloroquine sulphate is typically regarded as the first-line systemic anti-malarial medication⁵⁻⁶. The analysis of drugs has undergone quality control in the current study. In this study, two different types of methods—A 1% value of absorbance (Method I) and area under curve (Method II)—were created to study the medication hydroxychloroquine sulphate. Once a method has been developed, method validation must be carried out. In order to make sure that the precise requirements for the intended application are met, method validation entails conducting extensive analyses and offering objective proof. The method's suitability for routine application is primarily determined by determining whether it consistently produces trustworthy findings. Evaluation of the analytical process's capacity to produce reliable, consistent results is a key component of validation.⁷⁻¹⁹




Figure 1 — Chemical structure of Hydroxychloroquine Sulphate ($C_{18}H_{26}ClN_3O.H_2SO_4$)

Regulatory agencies receive unbiased data from the validation process that attests to the effectiveness of procedures and systems. Various factors, such as the analytical curve, linearity, limit of detection, limit of quantification, accuracy, precision, and robustness, are often included in the validation of analytical methods.²⁰⁻²¹ The quantification of hydroxychloroquine sulphate has been studied using a variety of analytical methods, including gas chromatography²²⁻²³, fluorescence spectroscopy²⁴⁻²⁵, chemiluminescence²⁶, plasmon resonance light scattering²⁷, planar chromatography²⁸, Raman spectroscopy²⁹, high-pressure liquid chromatography (HPLC)³⁰⁻³⁵, capillary zone electrophoresis³⁶⁻³⁷, micellar electrokinetic chromatography³⁸ and UV spectroscopy.³⁹⁻⁴¹ In this study, a novel, alternative,

and fundamental analytical method for hydroxychloroquine sulphate measurement is developed and validated. The procedure is developed in accordance with ICH (International Conference on Harmonisation) principles, guaranteeing that it complies with accepted business practises. The study demonstrates how putting this technology to regular use in the pharmaceutical business is feasible, dependable, safe, and cost-effective⁴²⁻⁴⁴.

2. EXPERIMENTAL SECTION

A computer was connected to a double-beam UV-vis spectrophotometer (Jasco V-630 and Shimadzu-1700 double beam) that had a 1 nm wavelength array and a pair of quartz cells that were spaced apart by 1 cm. Every weight was measured using an electronic balance.

2.1. MATERIALS AND METHODS

2.1.1. Chemicals and Reagents

Pharmaceutical grade Hydroxychloroquine Sulphate standard was obtained as generous gift from Wallace Pharmaceuticals Pvt Ltd, Mumbai, Maharashtra, India.

2.1.2. Instruments:

The Shimadzu -1700 double beam UV spectrophotometer system (Shimadzu, Milford, MA, USA), a silicon photodiode detector, and the Jasco V-630 UV-spectrophotometer were used to develop the analytical method. Shimadzu UV Probe (Ver. 2.21), data analysis software, was used to assess the outcomes. For all parameters, high precision analytical balances of the AUX220 model (Shimadzu, Mumbai) and calibrated glassware were utilised.

2.1.3. Solubility

Hydroxychloroquine Sulphate is readily soluble in water, only slightly soluble in methanol, and insoluble in alcohols, ethers, and chloroform. It is soluble in acids like HCL and Acetic acid.

2.1.4. Preparation of standard solutions


A stock solution containing 10 mg of HCQS was precisely weighed, diluted in 5 mL of 0.01N acetic acid, transferred to a 100 mL volumetric flask, sonicated for 15 minutes, and then volume was brought up to the mark using 0.01N acetic acid.

2.1.5. Preparation of sample solution

By precisely measuring tablet powder equal to 10 mg of hydroxychloroquine sulphate, the stock dilution (100 g/mL) of the marketed product was made in 0.01N acetic acid. The calibration curves were created by graphing the relationship between concentration and absorbance. This stock was diluted with water (10 g/mL of test solution) from 1.0 mL to 10 mL.

2.1.6. Determination of λ max

The greatest absorbance of hydroxychloroquine sulphate is observed at 329.4 nm (Figures 2 (a) and 9b) when the working standard solution of 10 g/mL is scanned in the UV range 400-200 nm.



2.1.7. Preparation of Calibration Curve

To achieve a final concentration in the range of 5-35 g/mL, appropriate dilutions of the standard stock solution were produced. Each produced solution's absorbance was evaluated at various 329.4nm wavelengths. The calibration curve, which had a correlation coefficient of 0.999 between concentration and absorbance, was plotted (Figure 2). the spectra and overlay of commercially available and API hydroxychloroquine sulphate, respectively.

2.1.8. Determination of A1% value⁸⁻¹⁰.

There may be a drop in light intensity when a beam of light passes through a transparent cell containing a solution of an absorbing substance.

Beer's Lambert law is represented mathematically as

$$A = \epsilon bc$$

Where,

A=absorbance or optical density

ϵ =absorptivity or extinction coefficient

b=path length of radiation through sample (cm)

c=concentration of solute in solution.

Both b and a are constant so a is directly proportional to the concentration c . When c is in gm/100 ml, then the constant is called A (1%, 1 cm).

$$A = A \frac{1\%}{1cm} bc$$

The preparation of a solution in a transparent solvent and the measurement of its absorbance at an appropriate wavelength can be used to quantify therapeutic substances using a spectrophotometer. The typical wavelength choice is the maximum absorption wavelength (max), where a tiny variation in wavelength scale setting has little impact on observed absorbance.

2.2. METHOD VALIDATION⁴⁵⁻⁵¹

The method was validated according to International Conference on Harmonization (ICH) guidelines.

2.2.1. Linearity and range

Analysing five or six separate concentration levels in the range of 5-35 g/mL was done to evaluate the linearity. Each solution's absorbance was measured at 329.4 nm against the procedure. A regression line equation and correlation coefficient for hydroxychloroquine sulphate were calculated from the calibration curve of absorbance versus concentration. The results were calculated three times, with the average value taken into account.

2.2.2. Accuracy (recovery test)

The method's accuracy was determined by how closely the measured value matched the sample's actual value. By recovering an active material of known purity, the accuracy of the approach was investigated. For the recovery, HCQS standard solutions at concentrations of 80, 100, and 120 g/mL were prepared. For each stage of recovery, three samples were made. The solutions were then examined, and using the calibration curve, percentage recoveries were determined.

2.2.3. Precision and stability

By doing one independent assay of a drug test sample containing 10 g/mL of the technique that was evaluated by the same analyst, system, and lab on various days, the precision of the method (intra-day and inter-day) was assessed. In order to evaluate the drug's stability, a stability research that kept the drug's working solution in 0.01N acetic acid for up to 48 hours at 2-8°C temperature and protection from light was conducted. The study looked for a decrease in absorbance compared to that of newly created solutions.

2.2.4. Ruggedness:

The ruggedness of the suggested procedures was tested to determine how non-procedure related elements like instruments and analysts would affect the results. In this investigation, hydroxychloroquine sulphate (20 g/mL) was analysed using the suggested procedures with

the help of two separate analysts and two different UV spectrophotometers (Jasco V-630 and Shimadzu-1700) under identical operational and environmental restrictions.

2.2.5. Robustness:

An analytical procedure's robustness, which indicates how reliable it is for routine analysis, relates to its capacity to stay unaffected by modest, intentional modifications in technique parameters. Analysing the same samples under various technique parameter settings, such as temperature, concentration fluctuations, etc., allowed researchers to assess the robustness of the method.

2.2.6. LOD and LOQ (Limit of Detection and Limit of Quantification)

Calibration curve was repeated and the standard deviation (SD) of the intercept was calculated. Then LOD and LOQ were calculated as follows:

$$\text{LOD} = 3.3 \times \sigma/S$$

$$\text{LOQ} = 10 \times \sigma/S$$

Where,

σ = Standard Deviation of response

S = slope of the calibration curve of analyte

2.3. Force Degradation Study

When designing UV spectroscopic methods, force degradation or stress testing is carried out to show specificity, particularly when little information about probable degradation pathways and degradation products is known. These studies also reveal details on the possible storage-related degradation pathways and end products. Exposure to heat, humidity, photo-stress (UV and VIS), oxidative conditions, and aqueous conditions over a wide pH range allows for a thorough evaluation of the force degradation mechanism⁹. According to ICH recommendations, investigations on forced degradation were conducted in order to create potential relevant degradants and test their spectral behaviour. Intentional degradation was attempted to stress conditions of acid hydrolysis (0.1 N HCl), neutral (with water), base hydrolysis (using 0.1 N NaOH), oxidative degradation (using 3% H₂O₂) and thermal degradation (photosensitive degradation).

2.3.1 Acid degradation

A study on acid breakdown was carried out by adding 2 ml of stock solution to a 10 ml volumetric flask. Two cc of 0.1 N HCl solutions were added, thoroughly mixed, and maintained at RT for 6 hours. The volume was then adjusted with diluent to achieve hydroxychloroquine sulphate concentration of 20 g/ml.

2.3.2. Neutral degradation

The volumetric flask was filled with 10 ml of water and 2 ml of the stock solution to conduct a neutral decomposition investigation.

2.3.3. Base degradation

Transferring 2 ml of the stock solution into a 10 ml volumetric flask allowed for the basic decomposition research to be completed. Two ml of the 0.1 N NaOH solution were added, thoroughly mixed, and left for 6 hours. To get 20 g/ml of hydroxychloroquine sulphate, the volume was then adjusted with diluent.

2.3.4. Oxidative degradation

Transferring 1 ml of the stock solution into a 10 ml volumetric flask was done to conduct the oxidative breakdown research. Three hours were given for the two ml of 3% H₂O₂ solutions to mix well. Following that, diluent was used to modify the volume to achieve hydroxychloroquine sulphate concentration of 20 g/ml.

2.3.5. Photosensitive degradation

A study on photosensitive deterioration was conducted using powder that had been weighed, combined with water, and then exposed to UV light or fluorescent light at 40 to 50 degrees Celsius for six hours. Records of the dilution spectra were made.

3. RESULTS AND DISCUSSION

It was discovered that hydroxychloroquine sulphate was highly soluble in 0.01N acetic acid and stable in acetic acid-water. Working standard solutions of the necessary concentration were made using these solvents throughout the experiment. In the concentration range of 5-35 g/mL, all proposed approaches adhered to Beer's-Lambert's law with correlation coefficient values under 1. An estimation of hydroxychloroquine sulphate tablets was carried out at working concentration to evaluate the applicability of the described methodologies to the pharmaceutical formulation. Plots were made of the HCQS absorption spectra in 0.01N acetic acid. The three levels used for the recovery study were 80, 100, and 120%. According to ICH criteria, all developed procedures underwent validation.


3.1. Calibration of HCQ

A 329.4nm average maximum was discovered. With the regression equation $y = 0.049x + 0.0014$ and the correlation coefficient of 0.999 ($r^2 > 0.999$), which reveals good agreement with the method's linearity, a linear relationship between the absorbance and the drug concentration was discovered at the concentration range of 5-35 g/mL (figure 2 and table 1).

Table 1: Calibration of HCQ

Sr. No.	Conc. (µg/ml)	Absorbance (329.4nm)	Method I	Method II
1	5	0.2457	491.4	0.2993
2	10	0.4898	489.8	0.4113
3	15	0.7354	490.3	0.5006
4	20	0.9812	490.6	0.6129
5	25	1.2289	491.6	0.7056
6	30	1.4767	492.2	0.7923
7	35	1.7087	488.2	0.8994

	Mean	490.58	0.6030
	±SD	1.3378	0.1977
	%RSD	0.2727	0.2375



3.2. Analysis of marketed formulation

This procedure resulted in a 100.12% estimate of the amount of hydroxychloroquine sulphate present in the tablet formulation. The percentage amount calculated from the tablet formulation shows that there was no excipient influence (Table 2).

Table-2: Assay of marketed formulation

Sr. No.	Wt. of sample taken(mg)	Amt. of estimation in avg. wt. of table (mg)	Observed value of AUC (mV)	Amount of estimation of drug (mg)	% Assay*	
					Method I	Method II
1	315.1	15.44	0.6114	10.03	100.53	100.05
2	311.4	15.45	0.6064	9.94	99.53	99.16
3	312.1	15.49	0.6099	10.08	100.74	99.48
4	302.4	15.45	0.6082	10.04	100.55	99.20
5	311.1	15.53	0.6080	10.00	99.67	98.92
6	310.1	15.52	0.6120	10.00	99.67	99.63
				Mean	100.12	99.41
				SD	0.707	0.3678
				%RSD	0.744	0.4053



*Each value is the mean of six reading.

3.2. METHOD VALIDATION

Developed methods were validated for linearity, accuracy, precision, ruggedness, and sensitivity as per the ICH guidelines.

3.2.1. Linearity and range

According to the findings from the linear regression, the calibration curves clearly displayed a solid linear relationship over the concentration range of 98–101% of the label claim. Figures 3(a) and 3(b) illustrate the calibration curves, and Figures 4 and 5 show the overlay of these concentrations.



3.2.2. Accuracy (Recovery Study)

Three distinct flasks labelled A, B, and C were used to administer the 20 g/ml drug solution. It was spiked with 80%, 100%, and 120% of the reference solution and diluted to a maximum of 10ml. Each solution peak's absorbance was calculated at a wavelength of 329.4 nm. The solutions are re-analyzed using the suggested techniques, and the outcomes of recovery investigations are shown in Table 2. The fact that the % RSD value is less than 2 shows that the approach is accurate (Table 3).

Table-3: Recovery study

Sr. No.	Level of drug taken %	Amount of estimation (mg)	Total amt. estimated (mg)	% Recovery*	
				Method I	Method II
1	80	10.16	7.85	100.62	98.03
2	100	9.83	10.01	99.24	99.89
3	120	10.07	12.15	100.57	101.19
			Mean	100.14	99.70
			±SD	0.7826	1.2984
			%RSD	0.7814	1.5950

*Each value is the mean of six reading.

3.2.3. Precision

The method's accuracy is described in terms of percent RSD. The data obtained demonstrated the assay's repeatability. Since the % RSD values were determined to be within the acceptable range, the approaches appear to be accurate (Table 4).

Table-4: Precision study

Sr. No.	Condition	Wt. of sample (mg)	Amt. of drug estimated (mg)	% Lable Claim*	
				Method I	Method II
1	Intra-day	15.45	9.99	100.05	100.38
2	Inter-day	15.45	9.87	98.87	99.49
3	Analyst 1	15.32	9.95	100.50	101.02
4	Analyst 2	15.48	9.98	99.75	99.29
5	Instrument 1	15.42	9.96	100.00	100.53
6	Instrument 2	15.32	9.95	100.51	100.89
			Mean	99.95	100.26
			±SD	0.6031	0.6569
			%RSD	0.6034	0.7177

*Each value is the mean of six reading.

3.2.4. Robustness

The investigation is carried out by adjusting the temperature conditions and by changing the concentrations (g/ml), as shown in Table 5 (based on the robustness study data).

Table 5: Robustness study

Sr.No.	Conditions		Amt. est. (mg)	% Estimation	
				Method I	Method II
1	Changes in conc. µg/ml	18	10.08	100.52	97.84
		20	10.01	99.85	99.64
		22	10.01	99.80	101.39
2	Temperature condition (°C)	50	9.95	99.97	99.74
		37	10.01	100.50	100.33
		25	9.72	97.64	100.05
			Mean	99.71	99.84
			±SD	0.9713	1.0595
			%RSD	1.0670	1.1627

*Each value is the mean of six reading.



3.2.5. Ruggedness

As indicated in Table 5, the findings of the ruggedness investigation were within an acceptable range with % RSD values less than 2. No statistically significant discrepancies across operators or instruments were found in the results, indicating the robustness of the devised procedures (Table 6); the recorded spectra are displayed in Figures 6(a) and 6(b).

Table 6: Ruggedness study

Sr. No.	Condition		Amount Estimated (mg)	% Estimation*	
				Method I	Method II
1	Different Analyst	Analyst 1	9.95	100.50	101.02
		Analyst 2	9.98	99.75	99.29
2	Intermediate Precision	Intra-day	9.99	100.05	100.38
		Inter-day	9.87	98.87	99.49
			Mean	99.79	100.05
			±SD	0.5958	0.6965
			%RSD	0.6893	0.8039

*Each value is the mean of three reading.



3.2.6. LOD and LOQ

Lower limit of quantification (LOQ) is determined to be 0.84 g/ml whereas LOD is found to be 0.24 g/ml. Low LOD and LOQ values with high precision demonstrate good sensitivity. With respect to the detection and quantification of the drug without significant equipment interference, these data suggest that the approach is very sensitive (Table 7).

Table 7: LOD and LOQ study

LOD and LOQ	Method I	Method II
Limit of Detection (LOD) ($\mu\text{g mL}^{-1}$)	0.2944	1.2546

Limit of Quantification (LOQ) ($\mu\text{g mL}^{-1}$)	0.8922	3.8018
---	--------	--------

3.3. Forced Degradation Studies

According to ICH requirements, forced degradation tests were conducted to create a potential relevant degradant and examine its spectral behaviour in order to evaluate the stability suggesting preparation of the suggested UV technique. With the help of 0.1 N HCl, water, 0.1 N NaOH, 3% H₂O₂, oxidative degradation, and thermal degradation (photosensitive degradation), intentional degradation was performed to stress the conditions. [Figure 7 (a-e)] (Table 8).

3.3.1. Acid degradation

The % acid degradation of sample after 3-4 hrs is found at approximately 39.45% and the recorded spectra is shown in figure 7b and table 8.

3.3.2. Neutral degradation

The neutral degradation after 3-4 hrs is approximately up to 18.78% and the recorded spectra is shown in figure 7a and table 8.

3.3.3. Base degradation

The degradation of sample after 3-4 hrs is recorded at approximately 96.75%. The recorded spectra is shown in figure 7c and table 8.

3.3.4. Oxidative degradation

The result of degradation after 3-4 hrs is found at approximately 75.64%. The oxidative degradation spectra is shown in figure 7d and table 8.

3.3.5. Photosensitive degradation

The results of degradation of sample after 5-6hrs of exposure is found approximately at 97.92%. The recorded spectra is shown in figure 7e and table 8.




Figure 7a- Degradation at Neutral Condition.




Figure 7b- Degradation at Acidic Condition.




Figure 7c- Degradation at Basic Condition.




Figure 7d- Degradation at Oxidative Condition.




Figure 7e- Degradation at Photosensitive Condition.

Figure 7 (a-e) : Spectra of Degradation Studies at Specific Conditions showing Degradation in Drug Sample; a) Degradation at Neutral Condition; b) Degradation at Acidic Condition; c) Degradation at Basic Condition; d) Degradation at Oxidative Condition; e) Degradation at Photosensitive study.

Table 8: Force degradation study

Forced Degradation parameter	% Recovery	% Degradation
Acid degradation	60.55	39.45
Base degradation	3.25	96.75
Neutral degradation	81.22	18.78
Oxidative degradation	24.36	75.64
Photosensitive degradation	2.08	97.92

*Each value is the mean of three reading.

3.4. Application to marketed tablet study

The current analytical technique was used to evaluate hydroxychloroquine in pharmaceutical tablet form (HCQS-200, 200 mg; Plaquenil, 200 mg). The label claim% (recovery SD) for the suggested UV-spectroscopic methods for HCQ were 100 1.2 (method-I) & 99.70 1.5 (method-II), respectively. The results of the suggested and available spectroscopic methods have been assessed using the student's t-test and the variance ratio F-test. According to computed results, the assay for methods I and II was determined to be 100.12% and 99.41%, respectively. This demonstrates that method I is more effective (99.71%) than a way that has been previously reported, however method II is less significant than a standard method. There has been not a significant variation between the results obtained by calculation of the suggested UV-spectroscopic system and results obtained by spectroscopic methods, demonstrating the same precision and accuracy within the evaluation of HCQ drug in its tablet dosage through the proposed technique.

CONCLUSION

The suggested method has various advantages. In the beginning, it uses water as the only diluent solution, reducing the need for additional chemicals. Second, direct dilution is used during the sample preparation phase, making it a quicker and more effective procedure. This strategy increases economic viability and saves time. Additionally, this approach encourages sustainability by minimising environmental effect by following the principles of green chemistry. Overall, these benefits make the suggested method an appealing and environmentally responsible choice. The approach is characterised by the following qualities, according to the validation process: linearity, efficacy, selectivity, precision, accuracy, and robustness across all examined parameters. Furthermore, because there were no appreciable discrepancies in the data produced from the two procedures, the methodology was deemed to be suitable for substituting the official method advised by the USP. In conclusion, it was determined that the employment of spectrophotometric methods utilising UV absorption was crucial for the testing and analysis of the medicine and dosage form containing hydroxychloroquine sulphate. It proved to be dependable and safe, establishing itself as a reliable method for this particular use.

Acknowledgements: We would like to express our gratitude to Wallace Pharmaceutical Pvt. Ltd. (Mumbai, India) for providing the pure drug sample (API). The Central Instrumental Lab. (UV-spectrometer), SKBCOP, Kamptee, facility utilized in this investigation was provided by Dr. Milind J. Umekar.

Declaration of competing interest: Not Applicable

Conflict of Interest: Not Applicable

Funding: Not Applicable

Authors' contributions: All authors have read and approved the manuscript. TM contributed in preparation primary content. She performed extensive literature survey and compile the content. TM contributed in preparation of figures and table. SR contributed in checking of manuscript and correction of grammatical mistake. SR contributed in preparation of figure. SR contributed in finalization of manuscript and in its correction. KR contributed in finalization of content, preparation of concrete manuscript and in schematic presentation of content

REFERENCES

- 1) Singh, A., Sharma, P., Gupta, R., Mondal, N., Kumar, S. and Kumar, M., 2016. Development and validation of UV-spectrophotometric method for the estimation of hydroxychloroquine sulphate.
- 2) Hydroxychloroquine sulphate | C18H28ClN3O5S - PubChem [Internet]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Hydroxychloroquine-sulfate.12:45pm>.
- 3) Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H., et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discovery*. 2020 Dec 18; 6(1):16.
- 4) Indian Pharmacopoeia 2020.
- 5) British Pharmacopoeia. Available from: <https://www.pharmacopoeia.com/ban-2012/ban-2017>.
- 6) Snigdha D., Mounika N., Nazneen A., Spandana R., Sravani P. Method Development and Validation for Estimation of Hydroxy Chloroquine Sulphate by Using UV Spectroscopy.
- 7) Kasture A., Mahadik K., Wadodkar S., More H., *Pharmaceutical Analysis Vol-II* By Nirali Prakashan, ISBN10:
- 8) Sharma Y. R. *Elementary Organic Spectroscopy Principles and Chemical Applications* (5th Ed.) S. Chand Publication.
- 9) Pavia D., Lampman G., Kriz G., *Introduction of spectroscopy* by Thomus learning.pg.no. 353.
- 10) Anderson R., Bendell D., Groundwater P., *Organic Spectroscopic Analysis*, ISBN 0-85404-476-0.

- 11) Birajdar A. S., Text Book for Uv-Visible Spectroscopy, Mahi publication (1 January 2019); ISBN-10: ISBN-13.
- 12) Tyagi O., Yadav M., Textbook of Spectroscopy, Anmol Publications PVT. Limited, 2002. ISBN, 8170413508.
- 13) Patil, P., Rangari, S., & Patil, P. (2020). Recent Research on Analytical Methods of Analysis of Artemether and Lumefantrine: A Review. *Himalayan Journal of Health Sciences*, 16-29.
- 14) Patil, P., & Rangari, S. (2020). Research on analytical methods of analysis of Ranolazine: A Review. *Himalayan Journal of Health Sciences*, 30-40.
- 15) Rangari, S. W., & Bari, S. B. (2022). Analytical Profiling of Sofosbuvir as NS5B Protein Inhibitor for Oral Drug Delivery: Method development and Validation. *Bulletin of Faculty of Pharmacy Cairo University*, 60(2), 4.
- 16) Patil D., Rangari S., Chaudhari S., Bhurat M., [Analytical Method Development for the Determination and Quantification of Ramipril in Pharmaceutical Formulation by HPLC](#). *International Journal for Research Trends And Innovation (IJRTI)* 7 (9), 910 - 915.
- 17) Rangari S., Rane B., Baviskar S., [Thin layer Chromatography of ibogaine from plant extract of Tebernantheiboga](#), *Journal of Current Pharma Research (JCPR)*, 5 (3), 1565-1568.
- 18) Perkampus H., Text book of Uv Visible spectroscopy and its application, Springer publication. eBook ISBN: 978-3-642-77477-5.
- 19) Thomas M., Ando D., Ultraviolet and Visible Spectroscopy: Analytical Chemistry by Open Learning, 2nd Edition. Wiley Publication. ISBN: 978-0-471-96743-9.
- 20) Vitha M. Textbook of Spectroscopy Principle and Instrumentation, Wiley publication. ISBN: 978-1-119-43664-5.
- 21) Kumar C., UV-VIS and Photoluminescence Spectroscopy for Nanomaterials Characterization, Springer Publication, ISBN: 978-3-642-27593-7.
- 22) Bodur S., Sezin E., Gunkara O., Bakırdere S. "Accurate and sensitive determination of hydroxychloroquine sulphate used on COVID-19 patients in human urine, serum and saliva samples by GC-MS." *Journal of Pharmaceutical Analysis* 11, no. 3 (2021): 278-283.
- 23) Sezin E., Bodur S., Öner M., Günkara O., Bakırdere S., "A simple and efficient derivatization strategy combined with switchable solvent liquid-liquid microextraction hydroxychloroquine methyl acetate-d 3-based quadruple isotope dilution gas chromatography mass spectrometry for the determination of hydroxychloroquine sulfate in biological fluids." *Rapid Communications in Mass Spectrometry* 36, no. 12 (2022): e9282.
- 24) Gaëlle N., Amoura Z., Combarel D., Lori L., Tissot N., Seycha A., Funck-Brentano C., Zahr N., "Development and Validation of a Fast Ultra-High Performance Liquid Chromatography-Fluorescent Method for the Quantification of Hydroxychloroquine and Its Metabolites in Patients with Lupus." *Therapeutic Drug Monitoring* 41, no. 4 (2019): 476-482.
- 25) Ramzy S., Abdelazim A., Osman A., Hasan M., "Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human

- plasma." *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 281 (2022): 121625.
- 26) Yi-Chia L., Ji-Fan L., Sheng-I. W., Shan-Che Y., Te-Fu T., Hung-En C., Kuang-Yu C., Thomas I., Sheng H., "Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis." *The Kaohsiung journal of medical sciences* 33, no. 5 (2017): 215-223.
- 27) George J., Mathew B., "Cyclodextrin-mediated gold nanoparticles as multisensing probe for the selective detection of hydroxychloroquine drug." *Korean Journal of Chemical Engineering* 38 (2021): 624-634.
- 28) Wioletta P., Dołowy M., Pyka-Pająk A. "Significance of Chromatographic Techniques in Pharmaceutical Analysis." *Processes* 10, no. 1 (2022): 172.
- 29) Thangavelu K., Wang T., Murugesan T., Anthuvan A., Kumar R., Ahmed F., Arshi N. "Structural growth of zinc oxide nanograins on carbon cloth as flexible electrochemical platform for hydroxychloroquine detection." *Chemosphere* 312 (2023): 137186.
- 30) Vincent L., Bourcier B., Cosson K., Lagarce F., Spiesser-Robelet L., Vrignaud S., "New liquid oral formulations of hydroxychloroquine: a physicochemical stability study." *Pharmaceutical Technology in Hospital Pharmacy* 6, no. 1 (2021).
- 31) Azab E., Noha F. "A validated UHPLC-MS/MS method for simultaneous quantification of some repurposed COVID-19 drugs in rat plasma: Application to a pharmacokinetic study." *Microchemical Journal* 178 (2022): 107321.
- 32) Ahmed A., Chang R., Tai W., Ke W., Michael YT Chow, Patricia Tang, Philip Chi Lip Kwok, and Hak-Kim Chan. "Inhalable hydroxychloroquine powders for potential treatment of COVID-19." *Journal of Aerosol Medicine and Pulmonary Drug Delivery* 34, no. 1 (2021): 20-31.
- 33) Lakeev, A., Abdrashitova Y., Bryushinina O., Frelikh G., Tsuran D., Zyuz'kova Y., Udut V., "Determination of Oseltamivir in Human Plasma by HPLC-MS/MS." *Pharmaceutical Chemistry Journal* (2023): 1-7.
- 34) Li G., Jing S., Huang Y., Li Y., Shi Y., Li Z., Li X., et al. "Enantiomers of chloroquine and hydroxychloroquine exhibit different activities against SARS-CoV-2 in vitro, evidencing S-hydroxychloroquine as a potentially superior drug for COVID-19." *BioRxiv* (2020): 2020-05.
- 35) Musazzi, U., Zanon D., Gennari C., Fortini M., Maximova N., Cilurzo F., Minghetti P., "Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation." *Data in Brief* 32 (2020): 106116.
- 36) Salvatore S., Zinellu A., Mundula N., Mangoni A., Carru C., Erre G.. "A Capillary Electrophoresis-Based Method for the Measurement of Hydroxychloroquine and Its Active Metabolite Desethyl Hydroxychloroquine in Whole Blood in Patients with Rheumatoid Arthritis." *Molecules* 27, no. 12 (2022): 3901.
- 37) Rozita M., Salavati-Niasari M., "Electrochemical sensor based on a chitosan-molybdenum vanadate nanocomposite for detection of hydroxychloroquine in biological samples." *Journal of Colloid and Interface Science* 613 (2022): 1-14.
- 38) Salvatore S., Zinellu A., Mundula N., Arduino A. Mangoni, Ciriaco Carru, and Gian Luca Erre. "A Capillary Electrophoresis-Based Method for the Measurement of

- Hydroxychloroquine and Its Active Metabolite Desethyl Hydroxychloroquine in Whole Blood in Patients with Rheumatoid Arthritis." *Molecules* 27, no. 12 (2022): 3901.
- 39) Singh A., Sharma P., Gupta R., Mondal N., Kumar S., Kumar M.. "Development and validation of UV-spectrophotometric method for the estimation of hydroxychloroquine sulphate." (2016).
- 40) Bhati, K., Mashru R. "Development and Validation of Extractive Spectrophotometric Method for Estimation of Hydroxychloroquine Sulphate by using Smartphone Application." *Journal of Drug Delivery and Therapeutics* 12, no. 3 (2022): 49-56.
- 41) Snigdha, D., Nerella Mounika, Afzal Nazneen, R. Spandana, and P. Sravani. "Method Development and Validation for Estimation of Hydroxy Chloroquine Sulphate by Using Uv Spectroscopy."
- 42) Guideline, ICH Harmonised Tripartite. "Validation of analytical procedures: text and methodology." *Q2 (R1)* 1, no. 20 (2005): 05.
- 43) Swartz M., Krull I., eds., 2018. Analytical method development and validation. CRC press.
- 44) Walfish S., 2006. Analytical methods: a statistical perspective on the ICH Q2A and Q2B guidelines for validation of analytical methods. *Biopharm International*, 19(12), pp.1-6.
- 45) Shrivastava, A., 2020. Analytical methods for the determination of hydroxychloroquine in various matrices. *Int. J. Appl. Pharm*, 4, pp.55-61.
- 46) Pannu, S., Akhtar, M.J. And Kumar, B., 2022. Analytical Methodologies For Determination Of Hydroxychloroquine And Its Metabolites In Pharmaceutical, Biological And Environmental Samples. *Current Pharmaceutical Analysis*, 18(3), Pp.273-290.
- 47) Swartz M., Krull I., (Eds.). (2018), *Analytical method development and validation*. CRC press.
- 48) Bensalah, N., Midassi, S., Ahmad, M.I. and Bedoui, A., 2020. Degradation of hydroxychloroquine by electrochemical advanced oxidation processes. *Chemical Engineering Journal*, 402, p.126279.
- 49) Bendjefal H., Mamine, H., Boukachabia, M., Aloui, A., Metidji, T., Djebli, A. and Bouhedja, Y., 2023. A Box-Behnken design-based chemometric approach to optimize the degradation of hydroxychloroquine in water media using the Fe (0)/S2O2-8/UV system.
- 50) Azeem, K., Ahmed, M., Mohammad, T., Uddin, A., Shamsi, A., Hassan, M.I., Singh, S., Patel, R. and Abid, M., 2022. A multi-spectroscopic and computational simulations study to delineate the interaction between antimalarial drug hydroxychloroquine and human serum albumin. *Journal of Biomolecular Structure and Dynamics*, pp.1-17.
- 51) Alessa, H., 2023. Recent spectrophotometric and electroanalytical methods used for the determination of quinoline-based compounds. *Journal of Umm Al-Qura University for Applied Sciences*, pp.1-13.

Abbreviations

HQC- Hydroxychloroquine sulphate

CQ- Chloroquine

HCl- Hydrochloric acid

NaOH- Sodium hydroxide

H₂O₂- Hydrogen Peroxide

A1%- Absorbance value of solution

AUC- Area under curve

LOD- Limit of detection

LOQ- Limit of quantification

SD- Standard deviation

%RSD- Relative standard deviation

ICH- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use

UNDER PEER REVIEW

Figures:




Figure 1 — Chemical structure of Hydroxychloroquine Sulphate (C₁₈H₂₆ClN₃O.H₂SO₄)










Figure 3 (a & b) - (a) Calibration curves for Method I & (b) Calibration curve for Method II








Figure 7a- Degradation at Neutral Condition.




Figure 7b- Degradation at Acidic Condition.




Figure 7c- Degradation at Basic Condition.




Figure 7d- Degradation at Oxidative Condition.




Figure 7e- Degradation at Photosensitive Condition.

Figure 7 (a-e) : Spectra of Degradation Studies at Specific Conditions showing Degradation in Drug Sample; a) Degradation at Neutral Condition; b) Degradation at Acidic Condition; c) Degradation at Basic Condition; d) Degradation at Oxidative Condition; e) Degradation at Photosensitive study.

Tables:

Table 1: Calibration of HCQ

Sr. No.	Conc. (µg/ml)	Absorbance (329.4nm)	Method I	Method II
1	5	0.2457	491.4	0.2993
2	10	0.4898	489.8	0.4113
3	15	0.7354	490.3	0.5006
4	20	0.9812	490.6	0.6129
5	25	1.2289	491.6	0.7056
6	30	1.4767	492.2	0.7923
7	35	1.7087	488.2	0.8994
		Mean	490.58	0.6030
		±SD	1.3378	0.1977
		%RSD	0.2727	0.2375

that there was no interference from excipients present in it (Table 2).

Table-2: Assay of marketed formulation

Sr. No.	Wt. of sample taken(mg)	Amt. of estimation in avg. wt. of table (mg)	Observed value of AUC (mV)	Amount of estimation of drug (mg)	% Assay*	
					Method I	Method II
1	315.1	15.44	0.6114	10.03	100.53	100.05
2	311.4	15.45	0.6064	9.94	99.53	99.16
3	312.1	15.49	0.6099	10.08	100.74	99.48
4	302.4	15.45	0.6082	10.04	100.55	99.20
5	311.1	15.53	0.6080	10.00	99.67	98.92
6	310.1	15.52	0.6120	10.00	99.67	99.63
				Mean	100.12	99.41
				SD	0.707	0.3678
				%RSD	0.744	0.4053

*Each value is the mean of six reading.

Table-3: Recovery study

Sr. No.	Level of drug taken %	Amount of estimation (mg)	Total amt. estimated (mg)	% Recovery*	
				Method I	Method II
1	80	10.16	7.85	100.62	98.03
2	100	9.83	10.01	99.24	99.89
3	120	10.07	12.15	100.57	101.19
			Mean	100.14	99.70
			±SD	0.7826	1.2984
			%RSD	0.7814	1.5950

*Each value is the mean of six reading.

Table-4: Precision study

Sr. No.	Condition	Wt. of sample (mg)	Amt. of drug estimated (mg)	% Lable Claim*	
				Method I	Method II
1	Intra-day	15.45	9.99	100.05	100.38
2	Inter-day	15.45	9.87	98.87	99.49
3	Analyst 1	15.32	9.95	100.50	101.02
4	Analyst 2	15.48	9.98	99.75	99.29
5	Instrument 1	15.42	9.96	100.00	100.53
6	Instrument 2	15.32	9.95	100.51	100.89
			Mean	99.95	100.26
			±SD	0.6031	0.6569
			%RSD	0.6034	0.7177

*Each value is the mean of six reading.

Table 5: Robustness study

Sr.No.	Conditions	Amt. est. (mg)	% Estimation		
			Method I	Method II	
1	Changes in conc. µg/ml	18	10.08	100.52	97.84
		20	10.01	99.85	99.64
		22	10.01	99.80	101.39
2	Temperature condition (°C)	50	9.95	99.97	99.74
		37	10.01	100.50	100.33
		25	9.72	97.64	100.05
		Mean	99.71	99.84	
		±SD	0.9713	1.0595	
		%RSD	1.0670	1.1627	

*Each value is the mean of six reading.

Table 6: Ruggedness study

Sr. No.	Condition		Amount Estimated (mg)	% Estimation*	
				Method I	Method II
1	Different Analyst	Analyst 1	9.95	100.50	101.02
		Analyst 2	9.98	99.75	99.29
2	Intermediate Precision	Intra-day	9.99	100.05	100.38
		Inter-day	9.87	98.87	99.49
			Mean	99.79	100.05
			±SD	0.5958	0.6965
			%RSD	0.6893	0.8039

*Each value is the mean of six reading.

Table 7: LOD and LOQ study

LOD and LOQ	Method I	Method II
Limit of Detection (LOD) ($\mu\text{g mL}^{-1}$)	0.2944	1.2546
Limit of Quantification (LOQ) ($\mu\text{g mL}^{-1}$)	0.8922	3.8018

Table 8: Force degradation study

Forced Degradation parameter	% Recovery	% Degradation
Acid degradation	60.55	39.45
Base degradation	3.25	96.75
Neutral degradation	81.22	18.78
Oxidative degradation	24.36	75.64
Photosensitive degradation	2.08	97.92

*Each value is the mean of three reading.

UNDER PEER REVIEW